[Subconjunctival chemotherapy in patients with acquired immunodeficiency syndrome. Experimental study of 3 clinical cases].

Revista medica del Instituto Mexicano del Seguro Social

PubMedID: 26383805

Melgares-Ramos MÁ, Carnesoltas-Lázaro D, Silveira-Melgares YS, Domínguez-Odio A. [Subconjunctival chemotherapy in patients with acquired immunodeficiency syndrome. Experimental study of 3 clinical cases]. Rev Med Inst Mex Seguro Soc. 2015;53(5):564-8.
BACKGROUND
Squamous carcinoma of conjuctive (SCC) is a rare tumour with different geographic frequency. The ethiology is multifactorial, and included high exposition to UV and also systematic infections (HPV and HIV). Those tumours have low potential of malignity, but occasionally this type of cancer is capable to provoke local recidive and distant metastasis and finally the death of patients. The aim of this work was to investigate the antitumoral response, the tolerable and safe doses of cysplatin preparation in three patients with HIV with recurrent SCC by subconjuctival and topical administration after conservative surgery.

METHODS
The patients were treated with cysplatin preparation. The treatment was about 3 months in 6 cycles. The patients were clinical follow since the last administration until update.

RESULTS
The evolution was favorable. The patients preserved the eyes and their vision without SCC recidive. One patient died about 2 years after he finalized the treatment with conservative vision and without tumoral activity and the cause was HIV infection.

CONCLUSION
Treatment with adjuvant chemotherapy to surgery subconjunctival is effective and tolerable in the population of patients treated.